Palvella Therapeutics (PVLA) completed the rolling NDA submission to the U.S. FDA for QTORIN 3.9% rapamycin anhydrous gel. The milestone is a positive regulatory progression toward potential review, though it does not itself confirm approval or timelines.
Palvella Therapeutics (PVLA) completed the rolling NDA submission to the U.S. FDA for QTORIN 3.9% rapamycin anhydrous gel. The milestone is a positive regulatory progression toward potential review, though it does not itself confirm approval or timelines.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
